UBS Group’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-9,700
Closed -$233K 9492
2023
Q4
$233K Hold
9,700
﹤0.01% 5690
2023
Q3
$212K Hold
9,700
﹤0.01% 5327
2023
Q2
$185K Hold
9,700
﹤0.01% 5535
2023
Q1
$188K Buy
+9,700
New +$169K ﹤0.01% 5422
2017
Q2
Sell
-1,400,000
Closed -$30.3M 7755
2017
Q1
$30.3M Buy
1,400,000
+900,000
+180% +$18.3M 0.02% 780
2016
Q4
$7.46M Buy
+500,000
New +$7.21M ﹤0.01% 1744
2015
Q1
Sell
-800
Closed -$1K 8970
2014
Q4
$1K Buy
+800
New +$1.25K ﹤0.01% 9533

Other funds holding EXEL

UBS Group's EXEL Position: Q1 2026 in Review

UBS Group reduced its Exelixis (EXEL) stake by 36% in Q1 2026, selling an estimated $57.1M and leaving 2,393,513 shares worth $103M. The position accounts for 0.02% of the portfolio, ranked #1029.

UBS Group first reported a position in EXEL in Q4 2014 and has held it in 46 quarters since. The position peaked at $163M in Q4 2025. 695 funds tracked by Wall St. Rank hold EXEL as of Q1 2026.

  • UBS Group held 2,393,513 shares of Exelixis worth $103M as of Q1 2026.
  • UBS Group sold 1,328,821 Exelixis shares in Q1 2026, an estimated $57.1M.
  • Exelixis made up 0.02% of UBS Group's portfolio in Q1 2026, its #1029 holding.
  • UBS Group first reported a position in Exelixis in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Exelixis position peaked at $163M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Exelixis as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.